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Cancer, one of the deadliest diseases of the world, is characterized by metabolic 
alterations that cause cells abnormal growth resulting in an uncontrollable proliferation. 
To reduce the mortality, increase the life quality and make the treatment more effective, 
early diagnosis is essential. Metabolomics is a promising area regarding cancer early 
diagnosis that detects a specific metabolite profile from biological samples using “case-
control” studies. This profile consists of a panel of small molecules derived from a global 
or target analysis that is detected through high-resolution analytical methods like the 
proton nuclear magnetic resonance (1H NMR). Urine is an appealing biofluid, obtained 
by a non-invasive way, rich in metabolites that reveals the recent homeostatic condition 
of an individual. 
Magnetic nanoparticles (MNPs), namely the magnetite (Fe3O4) and maghemite 
(Fe2O3) have been widely used in oncology for tumour targeting and contrast agent for 
magnetic resonance image diagnosis. However, their uncoated sorption capacity 
towards cancer biomarkers remains unknown.  
In this work, we aimed to evaluate the sorption capacity of uncoated magnetite 
and maghemite towards the extraction of different metabolites potential cancer 
biomarkers present on urine using the magnetic solid phase extraction followed by 1H 
NMR. To achieve this, the extraction methodology was optimised using spiked synthetic 
urine regarding the MNP type, amount, extraction time and temperature. The best 
optimization results were applied on urine samples of lymphoma and breast cancer 
patients and healthy volunteers to identify and quantify the potential biomarkers on a 
“case-control” study.  
Regarding the results, the 20-30 nm magnetite showed best cost-effectiveness 
ratio being the optimal extraction conditions obtained by using: a ratio of 0.2 mg/ml to 
extract during 5 min at room temperature with the addition of 1 ml of ultrapure water 
as elution solvent. On “case-control” study, most of the potential biomarkers followed 
the same changes, regardless of the cancer type.  










 O cancro, uma das doenças mais letais do mundo, é caracterizado por alterações 
metabólicas que causam o crescimento anormal das células levando à sua incontrolável 
proliferação. Para reduzir a mortalidade e aumentar a qualidade de vida, o diagnóstico 
precoce é essencial. A metabolómica, através do estabelecimento do perfil metabólico 
específico de amostras biológicas usando estudos de “caso-controlo” constitui-se como 
uma ferramenta promissora no diagnóstico precoce do cancro. Este perfil consiste num 
painel de pequenas moléculas derivadas de uma análise global ou alvo que é detetada 
através de métodos analíticos de alta resolução, como a ressonância magnética nuclear 
de protão (1H RNM). A urina é um biofluído obtido de forma não-invasiva rico em 
metabolitos que expressam a condição homeostática de um indivíduo. 
 As nanopartículas magnéticas (MNPs), nomeadamente a magnetita (Fe3O4) e 
maghemita (Fe2O3) têm sido muito utilizadas na oncologia para o direcionamento 
tumoral e como agentes de contraste no diagnóstico de imagem por ressonância 
magnética. No entanto, a sua capacidade de sorção para metabolitos potenciais 
biomarcadores do cancro ainda permanece pouco explorada. 
 No presente trabalho, será estudada a capacidade de sorção da magnetita e 
maghemita não revestidas, na extração de potenciais biomarcadores do cancro 
presentes na urina, utilizando a extração magnética em fase sólida seguida de análise 
por 1H NMR. Para isso, a metodologia de extração foi otimizada, utilizando urina 
sintética fortificada, em relação ao tipo de MNP, à quantidade sorbente, ao tempo e 
temperatura de extração. Os melhores resultados da otimização foram aplicados nas 
amostras de urina de pacientes com cancro da mama e linfoma e voluntários saudáveis 
para identificar e quantificar os potenciais biomarcadores num estudo de “caso-
controlo”. 
 A magnetita 20-30 nm apresentou a melhor relação custo-eficácia, nas seguintes 
condições de extração: uma razão de 0,2 mg/ml para extrair durante 5 min à 
temperatura ambiente, adicionando 1 ml de água como solvente de eluição. No estudo 
do “caso-controlo”, a maioria dos biomarcadores seguiu as mesmas mudanças, 
independentemente do tipo de cancro. 
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In this chapter, the main topics related with dissertation will be discussed. We will 
give a brief introduction of cancer disease and its impact, mentioning the current 
treatments and diagnosis as well the importance of early diagnosis. Right after we’ll 
mention some of the metabolic mutations that cancer has, namely the Warburg effect 
and Krebs (TCA) cycle as well as amino acid metabolism and profile. To conclude the 
cancer introduction, we’ll introduce metabolomics, explaining how it can help on the 
fight against cancer. 
After the cancer introduction, we’ll shortly introduce the biofluid urine, pinpointing 
its advantages and particularities regarding other non-invasive biofluids since is the 
biofluid chosen to develop the dissertation. Moreover, it is also mentioned some cancer 
diagnosis methodologies that are being developed using the metabolites found on this 
biofluid. 
Then we introduce how nanotechnology is contributing to the fight against cancer, 
focusing on magnetic nanomaterials, namely the iron oxide nanoparticles, which were 
the nanoparticles studied on this dissertation.  
The main techniques, magnetic solid-phase extraction (MSPE) and nuclear magnetic 
resonance (NMR), that were always used on this dissertation are also introduced 
through the explanation of their basic principles and why they were useful for the 
development of this dissertation. 
To settle this chapter, the main objectives of this thesis will be presented.  
1.1. Cancer overview 
Cancer is a well-known disease to world population characterised by metabolic 
alterations that cause cells abnormal growth resulting in an uncontrollable proliferation 
leading to death [1,2]. In the United States and Europe, is the second leading cause of 
death only being surpassed by cardiovascular diseases [3,4]. At the United States in 2018 
is estimated to appear 1.8 million new cases and 0.6 million deaths [3]. On Europe 1 in 
4 deaths are caused by cancer [5]. During 2018 is estimated to kill 1.4 million [6], largely 
affecting the European economy and productivity with a loss of 75 billion [4]. At 
Portugal, it is predicted that during 2018 will appear 58 thousand cases of cancer, killing 
29 thousand [7].  
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The most mortal cancer type in Europe and the United States is the lung cancer 
following by prostate on males and breast on females [1,3,6,8,9]. In Portugal, the most 
fatal cancer is prostate cancer on males and breast cancer on females succeeded by 
colorectum that affects both genders [7]. 
1.1.1. Current diagnosis 
The current diagnosis methods, shown in Figure 1, holds several drawbacks. The 
imaging methods lack sensitivity and specificity in addition to the health risks for 
patients and high costs. Thermography beside of being more cost-effective holds a lower 
sensitivity and specificity than imaging methods. The methodologies that ensure the 
diagnosis are invasive methodologies (biopsy and cytology), yet they have a high cost 










Figure 1  – Current cancer diagnosis methodologies [9–15]. 
1.1.2. Current treatments 
Currently, the cancer is treated in plenty of ways that are showed in Figure 2. 
However, most of them still have low selectivity and efficiency [16,17]. One of the main 
causes of death by cancer is the side effects of cancer treatments or relapse after the 
treatment [16–18]. Other death causes are the complications that cancer acquires on 
advanced stages such as cachexia [19,20], cancer-related cognitive impairment (CRCI) 
[21] or metastasis [12].    
Current cancer diagnostic methods: 
▪ Imaging methods: 
o Mammography; 
o Computed tomography (CT); 
o Magnetic resonance imaging (MRI); 
o Ultrasound (US); 







Figure 2 – Current cancer treatment procedures [17,18,22,23]. 
 
1.1.3. Importance of early diagnosis 
In order to improve the cancer treatment, decreasing its mortality and improve 
the life quality and expectancy, earlier diagnosis methodologies need to be developed 
[1,9,12,13,17,23–34]. The ideal diagnosis methodology must be non-invasive, 
inexpensive, fast and reliable to detect cancer on early stages and present a high degree 
of specificity/selectivity [12,13,28]. Figure 3 describes how early diagnosis contributes 
to better life quality and a mortality reduction [35].  
 
Figure 3 – Scenarios of early cancer detection through symptoms (A and B) or by screening (C). (A) Time intervals 
between symptoms appearance, diagnosis, and the start of treatment of cancer can be weeks to months, as well 
depends upon access to specialized care. (B) The better awareness of cancer symptoms may increase life expectancy 
and reduce serious consequences of the disease. (C) Before symptoms appear, screening in people at-risk leads to even 
earlier diagnosis and treatment of cancer, increasing life expectancy and reducing the consequences of cancer [35]. 
Current cancer treatment procedures: 
▪ Chemotherapy – use of drugs to treat cancer; 
▪ Surgery: 
o Curative (removes the tumour); 
o Palliative (side effect minimization); 
o Reconstructive (to restore a function that cancer damaged); 
▪ Radiation – use of high-energy rays; 
▪ Immunotherapy – use of antibodies to treat cancer; 
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With the development of early diagnosis methodologies, it will be possible to 
create screening programmes towards risky populations, improving their life quality 
(Figure 3 C) [35]. Currently, several screening projects for early detection are being 
developed and applied taking, for example, the EUROCOURSE [35] and the EUROMED 
CANCER Network project [36].  
 
1.2. Metabolic exchanges of cancer 
In order to achieve the well-recognised uncontrollable and abnormal 
proliferation characteristic of cancer cells as well their great adaptability, they undergo 
to several mutations that will lead to metabolism changes (Figure 4) [1,2,9,37–44] that 
affect several molecular mechanisms, from protein expression to molecular signalling’s, 
reflecting specific biochemical adaptations with the purpose of cancer cells acquire 
survival advantages [2,9,37–44]. 
Figure 4 – Overview of some cancer cells metabolism pathways. The metabolites in red colours represent possible 
cancer metabolites [41]. 
 
1.2.1. Warburg effect and TCA cycle 
One of the most well-known metabolism alterations that cancer does is the 
“Warburg effect”, discovered at the 1920s [2,29–31,37,39–41,43–48]. This effect affects 
the glycolysis pathway by consuming a higher glucose amount where, regardless the 
oxygen presence, produces lactate instead of pyruvate (anaerobic glycolysis) leading to 
a growth advantage since it synthetizes energy and the metabolites (nucleotides, lipids 
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and amino acids) needed for the proliferation (Figure 5) [2,29,31,39–41,43–47].  Initially, 
it was believed that this effect happened due mitochondria mutations that prevented 
they realize the oxidative metabolism, however recent studies show that the cancer cells 
mitochondria is also functional despite being disconnected from glycolysis 
[2,31,40,41,44]. This disconnection happens due to inactivation of the pyruvate 
dehydrogenase complex enzyme (PDH) that is the starting point of the citric acid cycle 
(TCA cycle also called “Krebs cycle”, where happens the oxidative metabolism and redox 
















Figure 5 – Glycolytic pathway that cancer cells use (Warburg effect) highlighting the metabolite synthesis used for 
proliferation. The red arrow is the pathway that healthy cells apply in the presence of oxygen to produce energy [40]. 
These studies also found that the mitochondria is the major contributor of 
energy synthesis on cancer cells [31,39,41]. As an adaptation to PDH inactivation to 
realize the TCA metabolism, the mitochondria uses as an alternative carbon source the 
glutamine realizing the glutaminolysis (Figure 6) [2,31,45,47]. This metabolic alteration 
synthesises the aspartate and oxaloacetate as well as alters the production of TCA 
intermediates (nucleotides, AA and lipids precursors needed for proliferation) 
[29,31,43,47]. An example of a TCA intermediate that supports the proliferation is the 
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citrate that is used to produce acetyl-CoA and oxaloacetate as well is used on lipogenesis 
[47]. 
There’re other mitochondria mutations that also are related to carcinogenesis, 
namely the mutations on the succinate dehydrogenase (SDH), isocitrate dehydrogenase 
(IDH) and fumarate hydratase (FH) [2,41,43,48]. On the SDH mutation case, it leads to a 
succinate accumulation that leads to an oncogenic signal transmission from 




Figure 6 – TCA cycle adapted to cancer cells. The red arrow represents the pathway that normal cells take but that on 
cancer cells is inactivated due to PDH inactivation [40]. 
 
One of the uses of the lactate, aside from contributing to the acidic and hypoxic 
environment, is to produce citric acid. This acid is produced by the neighbour cells 
helping the tumour to maintain the microenvironment that supports the tumour 
progression. Another use is the pyruvate conversion made by the cancer cells that are 
more oxygenated (near the blood vessels). Pyruvate is an important metabolite that 
have several uses and may even reprogram the cancer cells metabolism since it is a 
common intermediate between TCA cycle and glycolysis. It can be used to produce 
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alanine by transamination [31]. Usually, the pyruvate is used on the TCA cycle to produce 
energy for cancer cells (Figure 7) [40,46,47]. 
 
Figure 7 – Representation of lactate use on cancer cells [40]. 
1.2.2.   Amino acid metabolism and profile 
Amino acids (AA) are essential metabolites for several metabolisms, where they 
act as intermediates or as protein building blocks [28,37,49–51]. Since AA profile is 
widely dependant of metabolism conditions, metabolic changes caused by cancer 
affects the overall AA profile [37,43,46,49–51]. Since cancer needs AA for its 
proliferation, AA profile is a potential cancer marker, although some AA metabolic 
functions in cancer remain unknown [28,37,49–51]. 
An example of known AA alterations that is caused by carcinogenesis is the 
glutamine (Glu), that is abundant in blood and holds important functions on the 
organism such as nitrogen transport on plasma, AA level support in cells and proline 
production (which is needed to synthetize collagen) [31,40,46,51]. It can also be used to 
produce others AA, namely the alanine and arginine [40]. When the tumour is on 
hypoxic conditions (oxygen deprived), glutamine is used as a substrate for fatty acid 
synthesis [40,45]. On the tyrosine (Tyr), that is an aromatic AA originated from 
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phenylalanine hydroxylation, there’re studies that report that disorders on tyrosine 
concentration might be related to carcinogenesis [52]. The tryptophan (Trp) presence is 
essential for immune T cells proliferation, therefore in order to cancer cells increase 
their survival they metabolize the Trp using the indoleamine 2,3- dioxygenase (IDO) thus 
inhibiting the immune cell proliferation [45]. Currently, there’s some AA profile studies, 
showed in Table 1, that had been developed for cancer diagnosis. 
 
Table 1 – Alterations of amino acid profile in different types of cancer compared with controls. Keys: alanine (Ala), 
arginine (Arg), asparagine (Asn), citrulline (Cit), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), ornithine 
(Orn), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp). 
Cancer type 
AA significantly decreased 
(p < 0.05) 
AA significantly increased 
(p < 0.05) 
Lung [53] Asn, Cit, Gln, His, Trp Ile, Orn, Phe, Pro 
Breast [50] Asp, Gln, Gly, His Arg, Thr 
Breast [49] His, Pro, Thr  
Pancreatic [54] Ala, His, Trp Gly, Ile, Ser 
 
Is important to mention that there’s still remains a lot unknown and much to 
learn regarding the cancer metabolomics [2,30,37,39,45,47,55]. Indeed there’s several 
factors that affect the tumour metabolism, from the microenvironment to cell lineage 
and drug response [2,37,39,45,47,55]. An example of that is the reported cases where 
lung cancer cells in vitro prefer to use glutamine as TCA carbon source, whereas in vivo 
in mouse prefer to use the glucose [39]. Before the target, the cancer metabolism for 
diagnosis and therapy it is important to learn and identify the several compensatory 
pathways that the different types of cancer use to adapt and survive [2,39,40,45,47].  
 
1.3. Metabolomics 
Metabolomics is the research area where the small‐molecule metabolites in the 
metabolome are detected, identified and quantified in different biological samples, 
namely biofluids (Figure 8). Since a metabolome is a set of metabolites (that can be 
endogenous or exogenous) that are derived from metabolism, it is possible to know the 
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overall health status of individuals. An alteration on the metabolite(s) concentration can 
indicate that there’s a disease [28–31,49,55–65]. 
Metabolomics covers a wide range of metabolites (Figure 8), from metabolic 
intermediates to signalling molecules like hormones, for example. Due to that, it’s 
difficult to estimate the number of metabolites that exist on human metabolome. 
Currently, on the biggest and most comprehensive metabolite database known as 




Figure 8 – Example of how the metabolites found on different biofluids (e.g. blood and urine) can reflect the status of 
the entire individual organism, from health status to dietary habits [55]. 
 
Regarding cancer, since is already known that cancer alters the metabolism in 
several pathways, metabolomics is a promising area that helps its early diagnosis [9,26]. 
Some of the known cancer changes are the alterations on AA and glucose uptakes 
needed for its proliferation [55]. With the detection of certain metabolites that will be 
known as biomarkers, it is possible to detect cancer, namely the type and stage that 
prevails [55]. Metabolomics also has the potential to monitor cancer treatment and its 
eventual recurrence [1,9,26,28–31,38,42,45,55,59,61,64,72]. 
According to the National Cancer Institute, a biomarker is “a biological molecule 
found on body fluids or tissues that is a sign of normal or abnormal process or of a 
condition or disease” [73]. In other words, a biomarker is a molecule that depending on 
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its presence, absence or concentration can indicate a disease as well it’s stage and the 
therapeutic responses. In order to discover a biomarker, generally case-control studies 
are usually carried out for biomarker discovery [13,31,56,65,73]. 
 Is important to mention that a biomarker doesn’t have to be just a molecule. A 
biomarker also can be a set of molecules, where their concentrations will indicate the 
homeostatic condition of the individual, differentiating between the diseased and 
normal state. The ideal biomarker must fulfil some requirements namely the high 
specificity and sensitivity towards the disease (dropping this way the false positives and 
negatives cases), be economical and standardisable (providing good reproducibility) 
besides being ease of use (fast procedure) and provide clear results [13,28,29,73]. 
On metabolomics, there’s two different approaches for metabolite detection: 
untargeted and targeted metabolomics (Figure 9).  
 
 
Figure 9 – Description of the different approaches used in metabolite detection [60,61]. 
Metabolite approach detection: 
▪ Untargeted approach 
o Applies minimal sample treatment to prevent loss of metabolites; 
o Measures as many metabolites as possible; 
o Doesn’t have any knowledge of metabolites identity and nature; 
o Keeps many metabolites uncharacterized; 
o Is often related with hypothesis generating. 
▪ Targeted approach 
o Uses analytical standards to know the exact quantification of the 
metabolite; 
o Optimises the sample preparation methodology and analysis 
conditions to improve the detection and quantification; 




Regardless of the applied approach, the study of metabolomics follows the 
scheme represented in Figure 10 [60,61]. 
 
 
Figure 10 – Flowchart of a metabolomic study [30]. 
1.4. Urine as a source of biomarkers 
On the development of the ideal cancer detection methodology, the use of non-
invasive sampling procedures holds a high interest. This interest comes from the fact 
that these kinds of samples can be obtained on substantial amounts as well they can be 
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obtained as often as needed with better acceptance towards the patients since it is 
painless. Examples of non-invasive samples are the breath, saliva and urine [9,13]. 
Urine is an appealing biofluid due the high abundance and availability that can 
be easily collected and stored [15,27,29,31,38,61,62,64,65,73–75]. It has a high chemical 
diversity with a lower complexity (when compared with other biofluids) that facilitates 
the sample preparation for analysis and minimizes the interferences. Is primarily 
composed of urea, creatinine, small hydrophilic molecules like AA, soluble lipids, sugars, 
volatile compounds, organic acids and amines. It also has in lower amount hormones, 
proteins, metabolites, genetic material (DNA and RNA residues) and small inorganic salts 
that passed through the body reticuloendothelial filtration system [13,29,62,65,73,75–
78]. 
This biofluid is rich in metabolites that derive from several body processes 
whereas kidneys help to concentrate on acquiring the same metabolite concentrations 
as plasma [1,38,52,64,65,73,74]. These metabolites reflect the recent (last 24 h) 
homeostatic condition of an individual, showing it’s pathological or physiological state 
whereas can also show the individual gender, age, dietary habits, genotype, 
environmental exposures or drug intakes [27,29,38,52,57,62,64,65,73,76–79]. 
However, one of the most significant unresolved issues in the use of urinary 
metabolites for pathology diagnosis relies on the remarkable variance in urinary 
excretion volumes and subsequent variations in metabolite concentrations. This 
drawback can be countered with a standardization [62,73]. 
To develop a diagnosis strategy using urine, “case-control” studies are usually 
performed. On these studies, patients are compared with healthy controls where the 
differences detected can show a disease pattern which can be used for diagnosis [65]. 
Currently, several cancer diagnosis methodologies are being developed using “case-
control” studies to detect urine metabolites from prostate [1,14,38,61,72,75,78,80–82], 
bladder [15,38,61,65,72,75,83–88], ovarian [61,77], lung [1,13,38,65,72,89], breast 
[1,38,61,72,90], kidney [38,65], colorectal [1,38,64,65,91], esophageal [65], liver 




1.5. Nanotechnology contributions towards cancer 
An emerging and promising strategy in the metabolomics cancer field is the use 
of nanotechnology. Nanotechnology consists on the manipulation of the size or shape 
of a material at nanoscale level (size between 1-100 nm on at least one dimension) 
known as nanoparticles (NPs). This kind of materials have a high surface energy that 
leads to higher interactivity since there’s more atoms available to interact. They have a 
wide range of applications in different areas of science and technology, where the fight 
against cancer is one of the most promising [16,92–102]. 
Regarding cancer, nanomedicine uses several NMs, such as quantum dots, 
liposomes, dendrimers, silica NPs, polymersomes, metallic NPs, carbon nanotubes and 
magnetic NPs (MNPs). These NMs usually are able to accumulate more on tumours than 
normal tissues. Currently, the main application of these NMs against cancer is the 
creation of drug delivery systems (DDS) (Figure 11 and Table 2) that transports the 
anticancer drug directly to the tumour, reducing, by this way, the side effects and 




Figure 11–Examples of drug delivery systems (DDS) made with: A – Nanoparticle; B – Polymeric nanohybrid [16,17]. 
 
Moreover, these NMs can also act at cellular level when they are endocytosed 
by cells that leads to internalization of the anticancer drug. On Figure 12 is possible to 
observe some variations that DDS can have in order to fulfil their goal. Sometimes DDS 






 Figure 12 – Possible variations of DDS [96]. 
 
Another main use of NMs regarding cancer is the development of imaging agents 
that help to diagnose cancer with better accuracy. For this achievement, NMs are used 
as contrast agents that can be detected by CT, MRI, PET, US, magneto acoustic 
tomography (MAT) (an US variation) and radiodiagnosis. An example of NMs being used 
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1.6. Magnetic nanoparticles  
Magnetic nanoparticles (MNPs) are a class of NPs that can be manipulated under 
an external magnetic field. They are well known for their unique electrical, optical, 
chemical and magnetic properties that are advantageous to be used on a wide range of 
areas (like medicine, physics, biology and chemistry). These NPs are widely applied in 
many research fields where some of the main applications can go from sample 
preparation (Table 3 shows the improvement regarding conventional materials) to 
batteries and chemosensors [23,79,94,97,98,100,102,104–115]. 
Table 3 – Improvements of MNPs on several analytical processes compared with conventional materials [104] . 
 
On the field of nanomedicine, MNPs are highly researched due to their potential 
function at the molecular and cellular level of biological interactions, controlling their 
magnetism to achieve the desired uses. One of the most desired properties in this area 
is the superparamagnetism. Some of the research on this field is focused on the 
development of DDS, hyperthermia treatment or diagnostic methodologies, where 





Figure 13 – MNPs applications in cancer  [23]. 
MNPs properties and uses highly depend on the size, composition, surface 
chemistry and morphology. Regarding its magnetism, they are classified into five types 
(Figure 14): paramagnetic, diamagnetic, ferromagnetic, antiferromagnetic and 
ferrimagnetic. Paramagnetic materials have a weak magnetic moment and don’t 
maintain it when the magnetic field is removed. The diamagnetic materials only show 
magnetic moments under strong magnetic fields. Ferromagnetic materials have a strong 
magnetic moment and can maintain a magnetic moment after the magnetic field is 
removed. Antiferromagnetic materials usually are made of two different elements 
(usually metal oxides) that have doesn’t have a magnetic moment since the composed 
elements have magnetic moments on opposite directions, cancelling the magnetism.  
Ferrimagnetic materials are also composed of two elements that unlike 
antiferromagnetic, the magnetic momentums don’t cancel since they have different 
magnitudes. When there’s a magnetic field on antiferromagnetic and ferrimagnetic 
materials, they have the same behaviour as ferromagnetic.  During superparamagnetism 




Figure 14 – Types of magnetism [121]. 
 
There are numerous MNPs that can be classified into three classes: 
Metals – where only the metallic elements with magnetism are included, and they need 
an oxidation-protective layer. The only elements that fill this criterion are the 
ferromagnetic elements like cobalt, nickel and iron, where only iron isn’t toxic and can 
have uses on medicine [115]. 
Alloys – Constituted with ferromagnetic alloys like FePt, CoPt or FeNi. This MNP class 
tends to agglomerate and have low magnetism, having no use on nanomedicine [115]. 
Oxides – On this class are included the metallic oxides, and mixed oxides with different 
crystal structures (e.g., ferrite oxide) are included. Their magnetism properties depend 
on the MNP composition. Some MNP from this class hold promising applications on 
nanomedicine regarding cancer like magnetic hyperthermia (that is a tumour localised 
treatment) and a contrast agent [115]. 




Table 4 – Characterization techniques applied on magnetic nanoparticles showing their pros and cons [104] . 
 
1.6.1. Iron oxide NPs 
Iron oxide nanoparticles (IONPs) are a type of MNPs acknowledged for their low-
cost, controllable size, biocompatibility and nontoxicity, environmentally friendly nature 
and catalytic activity. The most common IONPs types are FeO, Fe2O3 (ferrite oxide) and 
Fe3O4 (magnetite). On the case of Fe2O3, there are four crystallographic phases 
denominated as hematite (α-Fe2O3), β-Fe2O3, maghemite (γ-Fe2O3) and ε-Fe2O3. Each 
crystallographic phase has different magnetic behaviour [115,122–126]. 
These MNPs have been widely used in several areas, depending on their size, 
shape, magnetism and surface properties. Some of their applications are: magnetic 
recording, humidity and gas sensors, microwave absorption, water treatment, catalysts, 
ferrofluids, inorganic pigments, pollutants extraction, magnetic seals and inks. On 
nanomedicine, they have been used as a cancer therapeutic agents, as contrast agent, 
magnetic hyperthermia and DDS development [34,95,109,121,123,125–128]. 
Among the different iron oxides types, only maghemite and magnetite have 
ferrimagnetism that is caused by their 3d spinel structure (on fcc cubic lattice subtype). 
These nanoparticles are one of the most promising materials regarding the cancer 
nanomedicine since they have colloidal stability, surface modification properties, 
46 
 
maximum surface area, low toxicity and biocompatibility. When they are smaller than 
20 nm, they become superparamagnetic being known as superparamagnetic iron oxide 
nanoparticles (SPIONs). This property is highly desirable on nanomedicine since that 
prevents agglomeration inside blood vessels [9,34,56,69,79,93,95–98,102,113,115–
122,124–133]. 
Nowadays on the cancer field, these NMs are used as MRI contrast agent (for cell 
and molecular imaging), magnetic hyperthermia (that can kill tumours) and DDS 
development, where usually they are functionalized or belong to the DDS core coated 
with another nanoparticle [23,134,135]. Sometimes, they can also be the shell of the 
DDS nanostructure [95,136,137]. Other applications on nanomedicine are tissue 
engineering/repair, cell labelling, detoxification, cell separation and isolation 
[9,23,92,95,115,121,122,126,127,129,130]. 
However, the sorption capacity of uncoated maghemite and magnetite remains 
vastly unknown, despite that there’s a large research for nanosorbents to sample 
preparation [79,94,101,102,110–112,114,138,139]. SPIONs can be synthetized with 
several methodologies that are categorized as chemical, physical or biological methods. 
Figure 15 shows methodologies that each synthesis category has as well the frequency 
that they are applied. On the Figure 16 it is possible to observe a schematic 
representation of some chemical synthesis methodologies of SPIONs and Table 4 









Figure 16 - Schematic representation of some chemical synthesis methodologies of SPIONs [132].
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Table 5 – Synthesis methodologies used to synthesize SPIONs 
Synthesis methodology Advantages Disadvantages References 
Co-precipitation 
- Rapid and simple methodology 
- Easy to maintain the synthesis conditions (pH, 
temperature and ionic strength) 
- Easy to scale up 
- Large particle size variation 







Oxidation method (wet 
chemical) 
- Easy to obtain small and uniform NPs at the 
molecular level 
- Synthesis takes a long time 




- Produces one-dimensional nanostructures 
with high purity 
- Simple methodology 
- Difficult to maintain the control of synthesis 
conditions and NP size 
- Requires high temperatures and vacuum 




- Good crystallization 
- Easy product morphology control 
- Requires high temperatures and pressure 







- Synthetizes high-quality monodisperse np, 
with narrow size range and good crystallinity 
- Demands high temperature 






- Precise control of the size, shape and 
distribution 
- Usage of large solvent amounts 
- Produces a low amount when compared with 
co-precipitation 





- Easy to scale up 
- Produces narrow size range, monodispersed 
np 




- Synthetizes high-quality monodisperse NPs, 
with a narrow size range 
- High reproducibility 
- Precise control of the conditions 
- Requires high temperatures and pressure with 
a segmented or continuous mix of reagents 






1.7. Basic principles of MSPE 
The need for preparation of biological samples is an essential step to lower the 
complexity of biological matrices as well it helps to pre-concentrate the desired 
compounds (Figure 17) [29,102,114]. To prepare the samples, there’re several 
extraction methodologies such as solid-phase extraction (SPE), microextraction by 
packed sorbent (MEPS), dispersive solid-phase extraction (dSPE) or magnetic solid-
phase extraction (MSPE), that can be applied, depending on the biological matrix and 
the target analytes. The ideal sample preparation technique should present a selective, 
fast, cheap and green extraction with a minimal sample loss and maximum recovery of 
the analyte [29,102]. 
 
Figure 17- Biological sample preparation for analysis  [102]. 
 Magnetic solid-phase extraction (MSPE) is as extraction methodology 
acknowledged for its simplicity, speed and practicality [101,102,104,110,112,114,138]. 
This methodology uses MNP as sorbents, simplifying the extraction procedure since with 
the help of a magnet, they are easily separated, overcoming this way, the need for 
packing columns that SPE requires [101,102,104,110,112,114,139,144]. The MNPs that 




 The general procedure is shown on Figure 18, where MNPs are dispersed on the 
sample that contains analytes and interferences that will be sorbed with the help of 
incubation or auxiliary radiation (sonication, ultrasonication).  
 
Figure 18 - Magnetic solid phase extraction scheme [104]. 
 
The MNPs will sorption the interferences or analytes. Depending on the extraction goal, 
there’s a division of two procedures: [79,101,104,111,112,144] 
1. If the goal is to pre-concentrate the analytes, MNPs will adsorb the analytes and 
retain them under a magnetic field while the sample is discarded. Then the 
analytes are eluted from the MNPs using an appropriate elution solvent, 
separating the MNPs from the solution with the help of a magnet to be analysed 
[79,104,111,112]. 
2. On the other hand, If the goal is to remove the interferences cleaning the sample, 







1.8. Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy is a very versatile and powerful analytical technique that was 
first described in 1938 by Isidor Rabi and commercially available in 1952 by Varian. It’s 
a well-known methodology used to identify molecules and discover their structure by 
measuring the nuclear magnetic interactions as well can be used to quantify the samples 
(qNMR) since each signal intensity is directly proportional to the number of 
atoms/nuclei present on that signal. This technique can be applied on small molecules 
as well as on large structures such as proteins. Currently, this technique is used on many 
fields such as medicine, physics, metabolomics, biochemistry, nanosciences and others 
(Figure 19) [25,42,58,60,145–147]. 
 
Figure 19 – Examples of NMR applications [25]. 
 
This technique relies on the nuclear spin of the atoms, which is a physical 
property where the atomic nuclei rotate on their own axis as a needle rotates towards 
magnetic fields. Usually, the nuclear spins are randomly oriented, depriving the 
macroscopic magnetization, but when are under a strong magnetic field, some of the 
nuclear spins become aligned parallelly to the applied field, generating a macroscopic 
ensemble magnetization (they become magnetized). In order to obtain the information 
of the sample, the sample is irradiated with radio waves pulses (also known as resonance 
frequencies) that will force the aligned atoms to leave their equilibrium position (parallel 
to the magnetic field) until the atomic nuclei become on a perpendicular plane. This 
influence creates a chemical shift (δ) that gets measured in parts per million (ppm). The 
δ values beside of depending on the external magnetic field, also depend of the atom 
microenvironment, generating this way a specific δ value that will indicate the atom 
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quantity and position as well their coupling, creating this way an NMR spectrum of the 
molecule(s) dissolved in a deuterated solvent [57,60,145,146]. 
The 1H (proton) NMR can provide important information on a sample (Figure 20). 
It is widely used for quantitative analysis (1H qNMR) on metabolomics since it provides 
quantitative information between intra-molecular and inter-molecular resonances 
[55,57,147,148]. 
 
Figure 20 – Summary of the information that 1HNMR can provide [57]. 
 
On cancer metabolomics, the techniques that provide more data usually are the 
NMR and mass spectrometry (MS). On the Figure 21 it is possible to observe some of 
the advantages and drawbacks of each technique. The NMR also has the advantage of 
being a non-destructive and non-invasive methodology that can be used on 
characterization of complex biomolecules like proteins. To identify the metabolites, 
target analysis is widely used although that this methodology is slow and expensive 
[30,31,38,42,55,56,58,61–63,65,67–72,149,150]. 
Information avaliable on 1HNMR: 
▪ Chemical shifts; 
▪ Signal multiplicites 
▪ Homonuclear coupling constants 
▪ Heteronuclear coupling constants 
▪ First order or second-order of the signal (multiplicity) 
▪ Half band-width of the signal 
▪ Integral of the signal 




Figure 21 – Comparison between NMR and chromatographic techniques. The properties highlighted in green are 
advantages and in red are drawbacks [25,61]. 
 
The 1H qNMR is highly appealing on metabolomics since protons are present on all 
metabolites. It performs a fast analysis with high reproduction that identifies and 
quantifies many metabolites present on complex mixtures (e. g. body fluids such as 
urine) without sample preparation or with minimal preparation. Regarding human urine, 
NMR techniques can detect and quantify more than 200 compounds, being an attractive 
metabolic profiling technique for disease diagnosis and monitoring by applying/with the 
application of “case-control” studies. However, sometimes the metabolites can suffer a 
signal overlay on all their characteristic peaks, making them unable to be identified and 
quantified. In order to make a 1H qNMR for metabolomics, the use of internal standard 
(that resonances at 0 ppm) is essential since helps to calibrate all spectra’s making easier 
the metabolites identification as well works as reference quantification peak, which is 
needed to quantify the metabolites. As reference substance for urine metabolomics, the 
Trimethylsilylpropanoic acid (TSP) is often used since is soluble on aqueous solutions in 
addiction that urine is a biofluid with low protein concentrations (TSP can bind with 






1.9. Thesis objectives 
The main objective of this Master thesis was to study the sorption capacity of the 
iron oxide NP, namely magnetite and maghemite, towards potential cancer biomarkers 
that can be found on urine. To reach that goal, a set of experiments were performed in 
particular: 
• Preparation of a synthetic matrix (synthetic urine, spiked with some known 
potential cancer biomarkers) that will be used on the study of sorption capacity 
of iron oxide np. It will also be used on the optimization of biomarker extraction 
methodology;  
• Creation of a metabolite library of potential cancer biomarkers used in this study. 
This library was used for metabolite identification using target analysis in order 
to know the biomarker characteristic peaks that could be used for identification 
and quantification. It was also used to know if the biomarkers suffered any 
overlay that prevent their identification;  
• Optimization of the biomarker extraction methodology. On this objective, 
several parameters that could influence the extraction efficiency were tested: 
o Nanoparticle type and amount; 
o Elution solvent; 
o Ultrasound adsorption time and temperature; 
• Application of the optimised conditions on a case-control study with real urine 
samples of control and cancer; 
During the thesis research, a side objective was also performed in order to check 
the validity of the use of iron oxide np as cancer biomarkers sorbent: 
• Compare the sorption capacity performance of iron oxide NP towards potential 
cancer biomarkers used on the study with the commonly used sorbents 
(LiChrolut and Amberlite XAD); 
It is important to mention that the 1H NMR analysis parameters were already 
previously optimized by our research group member Catarina Silva. 
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2. Materials and methods 
In this chapter, we report how it was studied the iron oxide NPs sorption capacity 
towards cancer biomarkers. To make it more understandable, this section is divided into 
two main sections: the synthetic urine preparation and the extraction procedure with 
the iron oxide np. Furthermore, we describe the optimization methods in detail as such 
the characterization procedure. At the end of this section, it is presented with accuracy 
the application of the optimized methodology to real urine samples. 
2.1. Materials and reagents 
Alanine (Ala, 98 %), creatinine (98 %), L-isoleucine (Ile, 98 %), leucine (Leu, 98 %), L-
lysine (Lys, 98 %), methionine (Met, 98 %), myristic acid (AMYR, 99.5 %), potassium 
chloride (99.5 %), Sodium Azide (99.5 %), Sodium Pyruvate (PYR, 99 %), Trimethylamine 
N-oxide (TMAO, 95 %), trimethylsilylpropanoic acid (TSP) (98 %), tryptophan (Trp, 98 %), 
tyrosine (Tyr, 98 %), urea (98 %) and valine (Val, 98 %) were provided by Sigma-Aldrich 
(Madrid, Spain). The calcium chloride (95 %), formic acid (FA, 98 %) lactic acid (ALAC, 85 
%), potassium di-hydrogen phosphate (99 %), sodium carbonate (99.8 %), sodium 
chloride (99 %), sodium hydroxide (NaOH, 98 %) and sodium sulphate (99 %) was from 
Panreac AppliChem (Barcelona, Spain). The ammonium chloride (99.8 %), LiChrolut®, 
magnesium chloride (99 %) and trisodium citrate (CRI, 99 %) is produced by Merck. The 
ethyl lactate (ELAC, 95 %) and diethyl succinate (SUCC, 99 %) were provided from Acros 
Organics (Geel, Belgium). Methanol (MeOH, 99.9 %) and acetone (HPLC grade) were 
supplied by Fisher Scientific (Loughborough, UK). Amberlite® XAD® 2 was provided by 
Supelco (Bellefonte, PA, USA). The deuterated water (D2O, 99.5 %) was provided by VWR 
(Radnor, PA, EUA). The ultra-pure (UP) water that was used on all experimental work 
was obtained through the Millipore Mili-Q direct 8 purification system with a resistivity 
higher than 18.2 MΩ.cm (at 25 ◦C). 
The nanoparticles (Figure 22) were all purchased on US Research Nanomaterials, 
Inc (Houston, TX, USA) with analytical grade. This company provides some 
characterizations of the product, namely SEM images as shown on Figure 22. 
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Figure 22 – SEM images of the nanoparticles used on this study. Legend: 1- Maghemite (γ-Fe2O3) 20 nm; 2- Magnetite 
(Fe3O4) 15-20 nm; 3- Magnetite 20-30 nm; 4- FeOOH Nanorods 50x10 nm  [151–154]. 
 
To prepare the samples and standards, several materials and types of 
equipment, including an analytical balance Ohaus Pioneer and a microbalance Mettler 
Toledo AT20, were used. The pH was adjusted with Mettler Toledo™ EL20 Benchtop pH 
Meter for Teaching and Learning (Mettler Toledo AG, Switzerland). The samples were 
filtered on 0.2 µm membrane PTFE filters (Merck Millipore, Milford, MA, USA) and the 
centrifugation was carried out in the refrigerated centrifuge Sigma 3-30k equipped with 
a rotor 12154H. The different analysis were performed using an NMR Bruker Ultrashield 
400 plus with the console Advance II+ 400 MHz. 
For 1H NMR analysis, the TSP solution at 0.1% was prepared with a mix on D2O 
of 1.5 M monopotassium phosphate and 2 mM of sodium azide. 
The real urine samples used on the final study were obtained from Urine bank 
(ACELab) frozen at −80 °C, collected previously at Hospital Nélio Mendonça within other 
studies. These samples were obtained from cancer patients (n=8, age=60.3 ± 10.2 years; 
Female non-smokers) that were diagnosed on Haematology–Oncology Unit of the Dr. 
Nélio Mendonça Hospital. Each individual provided a sample of morning urine (after 
overnight fasting) in a 20 mL sterile PVC container, which were immediately frozen at 
−80 °C and kept until being processed. 
All cancer patients gave their written informed consent for its volunteer 
participation in the study. The research was approved by the Ethics Committee of the 
Dr. Nélio Mendonça Hospital, being done in accordance with the Good Clinical Practice 
guidelines and with the ethical guidelines of the 2013 Declaration of Helsinki (DoH) 







2.2. Preparation of spiked synthetic urine 
2.2.1. Synthetic urine preparation 
The synthetic urine (SU) solution was prepared on UP water following the Wilsenach 
et al. [156] formula that is shown in Table 6. After preparing the SU solution, the pH was 
adjusted to 5.8 using FA at 10% or NaOH at 1M and filtered. The solution was divided on 
5 ml aliquots in 8 ml vials that were stored on the fridge until being used. 
 
Table 6- Composition of synthetic urine [156]. 
Compound Formula Concentration 
g L-1 mM 
Calcium chloride-2-hydrate CaCl2·2H2O 0.65 4.40 
Magnesium chloride-6-hydrate MgCl2·6H2O 0.65 3.20 
Sodium chloride NaCl 4.60 78.70 
Sodium sulfate anhydrous Na2SO4 2.30 16.20 
tri-Sodium citrate-2-hydrate Na3C6H5O7·2H2O 0.65 2.60 
Sodium carbonate anhydrous Na2CO3 0.02 0.19 
Potassium di-hydrogen phosphate KH2PO4 4.20 30.90 
Potassium chloride KCl 1.60 21.50 
Ammonium chloride NH4Cl 1.00 18.70 
Urea NH2CONH2 25.0 417 
Creatinine C4H7N3O 1.10 9.7 
  
2.3. Preparation of potential biomarker standard solutions 
The potential biomarker standard solutions were prepared according to the 
proportions observed in Table 7. Each solution was dissolved on UP water apart from 
myristic acid that was dissolved on MeOH. On the cases where the standards were on 
the liquid state (marked with * on Table 7), the adjustment calculations were performed. 
All standard solutions were stored on the fridge protected with Parafilm® and only were 












Volume (ml) Mass (g) Concentration (mg/ml) 
Alanine Ala 20 0.2 10 
Latic Acid ALAC 18 1.9 100 
Myristic Acid AMYR 20 0.2 10 
Ethyl Lactate ELAC 18 2 100 
Isoleucine Ile 20 0.2 10 
Leucine Leu 20 0.2 10 
Lysine Lys 20 0.2 10 
Methionine Met 20 0.2 10 
Pyruvate PYR 20 0.2 10 
Succinate SUCC 20 0.1 100 
Trimethylamine 
N-oxide 
TMAO 20 0.2 10 
Tryptophan Trp 100 0.2 2 
Tyrosine Tyr 40 0.2 5 
Valine Val 20 0.2 10 
2.3.1. Spiked of synthetic urine 
SU was spiked with cancer potential biomarkers, each 5 ml aliquot of SU was added 
the equivalent of 1 mg of each biomarker, acquiring the final concentration of 0.2 mg/ml 
of each potential biomarker. The relation between the biomarker concentration and the 
quantity of standard solution used for spike of the SU is observed in Table 8. 
 
Table 8 - Relation between the potential biomarker concentration and the quantity of standard solution used for spike 
of SU 






The biomarkers used to spike the SU were:  Alanine (Ala), Ethyl lactate (ELAC), 
Isoleucine (Ile), Latic acid (ALAC), Leucine (Leu), Lysine (Lys), Myristic acid (AMYR), 
Methionine (Met), Tryptophan (Trp) and Valine (Val). This procedure always was done 
with the solutions at room temperature (23 ºC) after they being vortex. The spiked SU 
when wasn’t applied extraction on the day was stored on the fridge. 
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All the potential biomarkers that were not used for the spike of urine, were used for 
target analysis for biomarker identification (Pyruvate (PYR), Succinate (SUCC), 
Trimethylamine N-oxide (TMAO) and Tyrosine (TYR)). 
2.4. Extraction procedure 
For the potential biomarker extraction, it was adapted the MSPE technique, where we 
disperse the MNPs on the sample, extract the potential biomarkers with the help of an 
ultrasound sonication and discard the sample solution while preserving the MNPs with 
the help of a magnet [79,104,111,138,139,144]. Then we add 1 ml of elution solvent on 
MNPs and we separate the MNPs by centrifuging for 15 min at 15,000 rpm (20627 rcf) 
and 10 °C and filtering through 0.22 µm PTFE syringe filters (BGB Analytik, VA, USA). On 
Figure 23 is observed the extraction scheme used in this study. Each extraction was 
carried out using spiked SU sample. Unspiked SU was used as a blank sample. 
At the end of the extraction the nanoparticles were always dried on a lab oven for 
2 days at 60 °C, then stored in vials separated by nanoparticle type for further studies. 
To make the nanoparticles identification easier during all work, each type of 
nanoparticle was numbered: 1 - Maghemite (Fe2O3) 20 nm; 2 - Magnetite (Fe3O4) 15-20 
nm; 3 - Magnetite 20-30 nm; 4 - FeOOH Nanorods 50x10 nm. 
 
Figure 23 – Magnetic solid phase extraction scheme. From [112] 
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2.5. Optimization parameters 
For the optimization of the experimental procedure, several parameters with 
influence on the extraction efficiency, namely extraction solvent, type of nanoparticles, 
nanoparticles amount, extraction time and temperature, were investigated.  
The optimization followed a univariate design represented on Figure 24, where the 
optimal results of the previous parameter were always applied on the following 
parameter. Each extraction was performed using spiked SU sample. Unspiked SU was 
used as blank.   
During the optimization, it was also tested the use of MNPs towards common 
sorbents such as LiChrolut® and Amberlite® XAD® 2. On this test, it was used 5 mg of 
each sorbent on SU and spiked SU extracting for 15 min on ultrasound. For elution, it 
was used 1 ml of UP water and the sorbents were separated with the help of 
centrifugation and filtration. 
 The conditions obtained at the end of optimization (a ratio of 0.2 mg/ml of 
nanoparticle 3 to extract during 5 min at room temperature with the addition of 1 ml of 








Figure 24 – Flowchart of the optimization methodology applied, mentioning the parameters and the used conditions.  
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2.6. 1H NMR Conditions 
The 1H NMR conditions were 400 MHz for 1H nucleus observation, at 300 K probe 
temperature. On each sample, a standard 1D 1H NMR spectrum was acquired, using a 
water suppression pulse sequence with water irradiation during relaxation delay and 
mixing time (‘noesypr1d’ from Bruker library, SW 12.0153 Hz, TD 64 K data points, 
relaxation delay 5 s, mixing time 200 ms, 128 scans).  
Each NMR tube was filled with 540 µL of the sample and 60 µL of TSP (used as 
chemical shift reference) except for real urine samples, where the proportions were 
adapted towards sample quantity. To wash the NMR tubes, it was added and discarded 
distilled water once and ketone three times, letting the remaining ketone evaporate at 
room temperature for at least a day before reuse the tube. 
To observe and calibrate the results obtained, the program topspin 4.0.4 was used. 
 
2.6.1. Identification of biomarkers (target analysis) 
In order to identify the cancer biomarkers on urine, a target analysis was made 
for each biomarker. On a 5 ml aliquot of SU, it was added the equivalent of 2 mg of a 
biomarker, acquiring the final concentration of 0.4 mg/ml. This solution was extracted 
for 15 min using 1 mg of the nanoparticle 3 and 1 ml of UP as an extraction solvent.  
To identify the SU characteristic peaks, direct analysis of SU was performed 
without any extraction procedure. 
 
 
2.6.2. Relative quantification of biomarkers 
To quantify the metabolites, it was used the Chenomx NMR Suite software 
developed by Chenomx, Inc. (Edmonton, AB, Canada) that makes possible to quantify 
hundreds of metabolites that are present on the software database using as a base the 
internal standard peak. [55,57,62,63,68,69,71,147] 
 
2.7. Application on real urine samples 
Prior to the application of extraction methodology, the pH of all real urine samples 
was adjusted to 5.8, followed by a 15,000 rpm centrifugation for 10 minutes at 10 °C to 
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separate the precipitations. After centrifugation, the supernatants were extracted with 
the best result methodology (that is found at section 2.5), adapting the proportions of 
the methodology (NP quantity and elution volume) towards the sample volume 
available. As a consequence, the sample volumes also had to be adapted for 1H NMR 
analysis. A total of 12 urine samples, described in Table 9, were extracted on this work.  
 
Table 9 – Characterization of urine samples included on the study. All samples are from females 
 Control Breast Lymphoma 
Number of samples (n) 4 4 4 
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3. Results and discussion 
On this chapter, the main results and their interpretation will be presented. To start, 
the data obtained from the target analysis will be shown in order to know the 
characteristic peaks of each biomarker as well as the urine characteristic peaks and the 
sorbent peaks. Right after the sorbents, performance results will be displayed where the 
common sorbents and the nanosorbents will be compared based on biomarker 
quantification. 
Then the results from the optimization methodology are presented. They follow the 
same order as the flowchart of Figure 24. Finally, the results obtained from the 
extraction of the real urine samples will be presented. The quantification of the control 








3.1. Identification of biomarkers (target analysis) 
The table 10 was made with the help of the target analysis and comparison of 
the data obtained with the Human Metabolome Database (HMDB) [60,65–71] 
biomarkers 1H spectra. This table shows all the biomarkers characteristic peaks in ppm 
that will be used on the biomarker quantification on this study. Is important to mention 
that the lactic acid suffered overlay on all its peaks; meanwhile the myristic acid results 
didn’t match with the HMDB results, leading to the exclusion of these biomarkers. 
Table 10 – Characteristic chemical shifts of potential target biomarkers. The identification peaks are highlighted.  Keys: 
a - biomarker that cannot be identified due to overlay on all their identification peaks; b - characteristic peaks that 
doesn’t match with HMDB characteristic peaks, making the biomarker not apt to be studied. 
Biomarker Biomarker initials Chemical shift (ppm) 
Alanine Ala 1.5; 3.8 
Latic Acid ALAC 1.3; 4.1a 
Myristic Acid AMYR 0.9; 1.6; 2.4; 3.1; 3.5b 
Ethyl Lactate ELAC 1.3; 4.1 
Isoleucine Ile 1.0; 1.2; 1.9; 3.6 
Leucine Leu 0.9; 1.7; 3.7 
Lysine Lys 1.5; 1.7; 1.9; 3.0; 3.7 
Methionine Met 2.1; 2.6; 3.9 
Pyruvate PYR 2.37 
Succinate SUCC 2.4 
Trimethylamine N-oxide TMAO 3.3 
Tryptophan Trp 3.3; 3.5; 4.1; 7.2; 7.3; 7.5; 7.7 
Tyrosine Tyr 3.0; 3.2; 4.0; 6.9; 7.1 
Valine Val 1.04; 2.3; 3.6 
 
Regarding Chenomx database, all the biomarkers except PYR are present. This 
leads to a total of 11 biomarkers that will be quantified on urine samples result and a 
total of 8 biomarkers that will be quantified on optimization and sorbent performance. 
Regarding urine, it was possible to identify the citrate (ppm 2.5 and 2.7), 
creatinine (ppm 3.1 and 4.2) and urea (ppm 5.8) that can be observed on Figure 25. 
Sometimes, in some published results, creatinine and citrate are used as cancer 
biomarkers. However, they won’t be considered biomarkers on this study since they are 
one of the main urine constituents, making the standardization of their amounts 




Figure 25 – 1H NMR spectra of synthetic urine in D2O. Legend: 1 – Citrate; 2 – Creatinine; 3 – Urea. 
3.2. Sorbents performance 
The sorbents performance towards the potential cancer biomarkers are 
displayed on Table 11 and Figure 26. Is possible to highlight that the nanoparticle 3 
(Magnetite 20-30 nm) extracted the biomarkers with more efficiency, namely the Ile, 
Leu, Lys and Val. 
This demonstrates that nanosorbents may be better than common sorbents. 
Aside from the simpler extraction methodology, the nanosorbents show a promising 
utility regarding the metabolite extraction that are potential cancer biomarkers. 
 
Table 11 – Sorbent efficiency towards the targeted potential biomarkers. Keys 1 - Maghemite (Fe2O3) 20 
nm; 2 - Magnetite (Fe3O4) 15-20 nm; 3 - Magnetite 20-30 nm; 4 - FeOOH Nanorods 50x10 nm. 
Biomarker 
Concentration [mM] Best sorbent 
Maghemite 










LiChrolut® Amberlite® XAD® 2  





 3.43 2.42 4.16 4.44 3.85 3.92 4 
Isoleucine  1.78 1.81 2.82 1.24 2.42 2.70 3 
Leucine  2.30 2.07 3.64 1.94 2.75 2.78 3 
Lysine  1.66 1.14 1.76 1.07 1.49 1.46 3 
Methionine  1.39 2.09 1.72 0.92 1.35 1.42 2 
Tryptophan  1.16 0.70 1.51 1.28 1.81 0.85 LiChrolut® 




3.3. Extraction optimization 
3.3.1. Extraction solvent 
Observing the data present on Figure 27 is possible to see that only the UP water 
or deuterated water were suitable to elute the potential cancer biomarkers. Due to 
economic reasons, UP water was chosen as elution solvent for this study. 
3.3.2. Nanosorbents 
The results of the nanosorbents are shown on Figure 26 and Table 12 altogether 
with the common sorbents. It is possible to observe that the nanoparticle 3 stands out 
on the extraction of several biomarkers (Ile, Leu, Lys and Val).  
The nanoparticle 2 was the nanosorbent that extracted more methionine, 
followed by nanoparticle 3. Meanwhile, the nanoparticle 1 doesn’t stand out on any 
biomarker.  
Aside from the nanorods (nanoparticle 4) being the nanoparticle that extracted 
more ethyl lactate, their extraction performance on other biomarkers is lower than the 
other nanosorbents. In addition, this NM is not magnetized, making the extractions 









Figure 27 - 1H NMR spectra of solvent extraction optimization in D2O
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3.3.3. Nanosorbents amount 
The 1H NMR spectra’s that show the nanosorbents amount influence towards 
the potential cancer biomarkers are present on the Figures 28-30.  
 Observing the spectra of the nanoparticle 1 in Figure 28 is notable that as the 
nanosorbent amount increases, the biomarkers extraction efficiency increases. 
However, as present on the figures of annex B (page 106), the use of high amounts of 
nanosorbent leads to high variation degree in the biomarker extraction when doing 
replicas. Due to that, the ideal amount that balances the extraction performance and a 
low variation degree is the 5 mg. 
 On magnetite nanoparticles (nanoparticle 2 and 3), where the spectrums are 
found on Figures 29 and 30, is perceptible that the biomarker extraction efficiency 
doesn’t change much regardless the amount of nanosorbent. For this reason, the ideal 
amount of magnetite nanoparticles is 1 mg. 
 
3.3.4. Extraction temperature 
Since the extraction at room temperature was already shown on previous 
results, namely on the Figures 26-30, only the extraction at hot temperatures is 
displayed on Figure 31. Observing the spectra is possible to see that the nanosorbents 
didn’t manage to extract the biomarkers with the same efficiency as it extracts at room 
temperature, making the use of hot temperatures not suitable for extraction.  
It was also observed that all the nanoparticles that underwent this extraction had 
partly lost their magnetic properties and agglomerated. An explanation for that is the 
rearrangement of the ordered magnetic moments, which decreases as the temperature 


















Figure 31 - 1H NMR spectra of extraction in D2O carried out at 70 ºC 
 
3.3.5. Extraction time 
As observed on the Figures 32-34, is it notable that the lower extraction time 
leads to a better extraction performance on any nanosorbent, with the best extraction 
time being 5 minutes. Knowing that, Figure 35 was made as a comparison of the 
nanosorbents under their optimum extraction conditions.  
Observing the data, the nanoparticle 1 and 3 are the nanosorbents that have 
better extraction efficiency, being that the extraction performance between these 
nanoparticles is very similar. Considering the cost-effectiveness ratio, which is an 
important parameter for scale up and routine analysis, the best nanosorbent to use is 
the nanoparticle 3 since on its optimum conditions uses 5x less amount than 
nanoparticle 1 and/ as well is the cheapest nanosorbent.  
The best extraction conditions that were used on urine extraction are:   a ratio of 
0.2 mg/ml to extract during 5 min at room temperature with the addition of 1 ml of UP 


















Figure 35 -1H NMR spectra of best optimization conditions in D2O. Keys 1 - Maghemite (Fe2O3) 20 nm; 2 - Magnetite (Fe3O4) 15-20 nm; 3 - Magnetite 20-30 nm; 4 - FeOOH Nanorods 50x10 nm.
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3.4. Application on real urine samples 
 
On Table 12, we observe a comparison of the biomarker’s quantification of real 
urine samples. On breast cancer (BC), it is notable that the majority of the potential 
cancer biomarkers have a lower amount on breast cancer, regardless if they are AA (Ala, 
Leu, Lys, Met, Tyr and Val) or belong the other pathways (ELAC), which is expected since 
cancer cells consume the metabolites in order to proliferate. 
 The biomarkers that don’t follow that pattern are the TMAO and Trp, that have 
higher amounts on BC meanwhile SUCC and Ile amount remains unchanged. On the case 
of Ile, is important to note that this metabolite usually was below the limit of detection 
or wasn’t present on urine, being unfit for use as a biomarker. Regarding Ala metabolite, 
the behaviour didn’t follow what has already been reported by Simińska et al. [28]. 
Unlike BC, most biomarkers have higher amounts on lymphoma (LYM) than 
control (Met, TMAO, Trp, Tyr and Val). The biomarkers that don’t follow that pattern are 
the Ala, ELAC and Leu, that on lymphoma have lower amounts while Ile, Lys and SUCC 
remain unchanged. 
Is remarkable that among the different types of cancer studied, the biomarker 
majority (Ala, ELAC, Ile, Leu, SUCC, TMAO and Trp) follows the same behaviour. 
However, the biomarkers Met, Tyr and Val had a higher amount on LYM than BC 
meanwhile the Lys remain unchanged on LYM while on BC had a lower amount. 
It is important to note that few urine samples were used, leading to a high 
standard deviation in all cases. To obtain more sturdy results that will lead to better 
observations, it is necessary to extract more urine samples.
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Table 12 - Biomarker quantification of real urine samples 
 
Biomarker 
Concentration in urine samples [mM] 
Status 
Control (n=4) Breast cancer (BC) (n=4) Lymphoma (LYM) (n=4) 
Average SD Range Average SD Range Average SD Range Control x BC Control x LYM 
Alanine Ala 0.54 0.32 0.17-0.87 0.32 0.12 0.16-0.45 0.32 0.13 0.20-0.47 ↓ ↓ 
Ethyl Lactate ELAC 0.58 0.14 0.44-0.71 0.36 0.09 0.30-0.49 0.47 0.13 0.34-0.65 ↓ ↓ 
Isoleucine Ile 0.01 0.01 0-0.02 0.01 0.01 0-0.02 0.01 0.01 0-0.02 − − 
Leucine Leu 0.05 0.06 0-0.13 0.03 0.03 0.01-0.07 0.03 0.02 0.01-0.05 ↓ ↓ 
Lysine Lys 1.22 0.47 0.58-1.69 1.08 0.63 0.48-1.94 1.22 0.54 0.71-1.99 ↓ − 
Methionine Met 0.57 0.62 0.13-1.49 0.23 0.09 0.15-0.36 3.86 4 0.21-7.75 ↓ ↑ 
Succinate SUCC 0.09 0.03 0.07-0.13 0.09 0.05 0.04-0.14 0.09 0.05 0.04-0.14 − − 
Trimethylamine 
N-oxide 
TMAO 0.21 0.12 0.05-0.33 0.55 0.55 0.17-1.37 0.31 0.25 0.10-0.66 ↑ ↑ 
Tryptophan Trp 6.21 3.93 2.94-11.8 8.14 3 4.34-11.03 10.12 10.36 4.55-25.66 ↑ ↑ 
Tyrosine Tyr 0.27 0.15 0.07-0.43 0.1 0.02 0.07-0.12 0.37 0.24 0.12-0.58 ↓ ↑ 

















4. Conclusions and future work 
In this thesis, it was explored a novel use of uncoated maghemite and magnetite 
as nanosorbents to explore its potential to isolate urinary metabolites potential cancer 
biomarkers present in urine samples from breast and lymphoma cancer patients and 
control group. These nanosorbents, namely the 20-30 nm magnetite, showed better 
results when compared with common sorbents, showing a promising utility regarding 
the metabolite extraction of potential cancer biomarkers.  
Regarding the optimization with the optimum conditions, the nanosorbent that 
showed the best cost-effectiveness ratio was the 20-30 nm magnetite. The ideal 
conditions for the extraction with this nanosorbent were: a ratio of 0.2 mg/ml to extract 
during 5 min at room temperature with the addition of 1 ml of UP water as elution 
solvent. 
On case-control study, most of the biomarkers followed the same changes, 
regardless of the cancer type. However, it is important to note that few urine samples 
were used, leading to high standard deviations in all cases. In the future, it will be 
necessary to apply the extraction methodology optimized in this thesis on a statistically 
significant quantity of urine samples (control and cancer) in order to obtain more robust 
and confident results. There will also be the need of applying a multiple extraction test 
to see the retention capacity of magnetite. It would be very interesting to test the 
extraction of different types and stages of cancer in order to study possible significative 
alterations. In addition, a washing methodology for magnetite recover would be 
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A. Poster presented at MAD-Nano 18 
 
Figure 1A – Poster presented at MAD-Nano 18 – 30th of November to 2nd of December 2018 – Madeira island, 
Portugal. Mariana P Santos, Catarina Silva, Ana Olival, João Rodrigues & José S Câmara, Exploratory evaluation of the 
potential of magnetic NPs as powerful sorbents for extraction of cancer biomarker
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B. Supplementary data regarding the nanoparticle 1 (maghemite 20 nm) amount 
Figure 2A - 1H NMR spectra of potential cancer biomarkers after extraction (n=3) from SU with 20 mg of maghemite 20 nm (nanoparticle 1) in D2O. 
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Figure 4A – Relation of the maghemite different amount (1 mg, 2.5 mg, 5 mg, 10 mg and 20 mg) on different samples. 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-financed by: 
 
 
  
UID/QUI/00674/2013 
CQM +M1420-01-0145-FEDER-000005 
